Quantum Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Mar 31, 2023 and accepted by EDGAR at Mar 31, 2023, 21:18 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$27.4m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$23.6m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$28.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $114.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2022-12-31 | $17.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2022-12-31 | $17.9m | ifrs-full:CurrentAssets |
| Total assets | At period end2022-12-31 | $38.4m | ifrs-full:Assets |
| Current liabilities | At period end2022-12-31 | $7.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2022-12-31 | $7.9m | ifrs-full:Liabilities |
Source: SEC EDGAR, the filing index for accession 0001062993-23-008232. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.